Service Optimization of Prostate Cancer Oral Therapy Pathway

This document is a report detailing a collaborative working project between Astellas Pharma Ltd and Royal Devon University Healthcare NHS Foundation Trust focused on optimizing the Prostate Cancer Oral Systemic Anti-Cancer Therapy (SACT) pathway. The objective of the project is to conduct a service review of the Prostate Cancer Oral SACT Novel Hormone Therapy pathway in partnership with Bionical Solutions Ltd. The aim is to redesign the pathway to enhance the efficiency of the cancer center's prostate cancer services. The report outlines the burden of new prostate cancer cases on NHS capacity, highlighting that 26% of all new cancer cases in males are prostate-related, with 48,500 patients diagnosed annually. The optimization program seeks to address inefficiencies, delays, and bottlenecks in the current service, ultimately improving patient well-being, reducing waiting times, and enhancing service delivery within prostate cancer clinics.